EXOZNasdaqBiological Products, (No Diagnostic Substances)US GAAP · USD

eXoZymes Inc

ExoZymes Inc. is a U.S.-based biological products company focused on research-driven product solutions and collaborations with partner companies and other clients. Based on its recent filings, the company appears to operate as an early-stage R&D and commercialization platform whose business depends on external funding, research partnerships, and access to imported inputs and capital markets.

Ask about the company
Operating profit (EBIT)-9.7m USD
−63.8 %y/y
Net income-9.2m USD
−56.3 %y/y
Free cash flow-6.7m USD
+25.1 %y/y

Fiscal year 2025 · change from previous year

Development 2023–2025

-10-8-6-4-202m USD2023: 0.07 m USD2023: EBIT -1.8 m USD20232024: 0.07 m USD2024: EBIT -5.9 m USD20242025: EBIT -9.7 m USD2025-9.7
RevenueOperating profit (EBIT)
Ask Clarifo about eXoZymes Inc

Business

Share of revenue
Biological product solutions45 %

Core biological products and related solutions developed for partner companies and clients.

Research and development services35 %

Collaborative R&D work supporting product discovery, development, and validation.

Partner support and commercialization services20 %

Assistance to partner companies in advancing development and preparing for commercialization.

Customers

The company serves partner companies and other clients that need biological product solutions and research collaboration. Its customer base appears to include organizations dependent on government research funding, external capital, and imported equipment or materials to advance development programs.

Partner companies

Companies that use Exozymes' solutions and collaboration to advance product development.

Other clients

External clients purchasing research support and product solutions for development work.

Grant-funded research organizations

Universities and research enterprises that may collaborate when public funding is available.

Capital-constrained development programs

Early-stage programs that need outside funding to continue work based on the company's solutions.

Strategy

Exozymes' near-term strategy appears centered on sustaining research activity, preserving access to funding, and supporting partner-company development programs. The company also needs to manage tariff and import-related disruptions while maintaining the ability to raise capital and secure collaborative research relationships.

Maintain research funding accessShort term

Government grants and related funding appear important to sustaining research and partner development work.

Support partner-company executionShort term

The business depends on partner companies and clients continuing development work based on its solutions.

Reduce trade and sourcing disruptionMedium term

Tariffs and import/export changes may raise costs and restrict access to equipment or inputs.

Improve capital accessMedium term

The company states that policy changes may make private fundraising more difficult.

Geography

The company is headquartered in Monrovia, California, and its filings indicate exposure to U.S. trade policy, tariffs, and federal funding decisions. No country-level revenue disclosure was provided, so the geographic profile is best understood as U.S.-centric with indirect international exposure through imports and trade policy.

Risks

The most visible risks are policy-driven: tariffs, import/export restrictions, and reductions in research funding could directly disrupt operations and weaken partner demand. As an early-stage biological products company, Exozymes also faces typical execution risk around funding availability, supplier access, and the ability to convert research activity into durable commercial programs.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Reduction in research grants and federal funding1Difficulty raising private capital2Tariffs and import/export regulation changes3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Reduction in research grants and federal fundingImpact: HighLikelihood: High

    Lower public funding could reduce collaborative research activity and partner development work.

    ExposurePartner companiesClientsResearch collaborators
  2. Difficulty raising private capitalImpact: HighLikelihood: High

    Management states that policy uncertainty may make investors less willing to fund the company.

    Exposure: Corporate financing and working capital

  3. Tariffs and import/export regulation changesImpact: HighLikelihood: Medium

    The company says tariffs may raise costs and restrict access to imported equipment and supplies.

    Exposure: Imported equipment and general operating inputs

  4. Early-stage commercialization execution riskImpact: Medium

    The business depends on advancing research solutions into usable products and programs.

    Exposure: Product development and partner retention

Ask Clarifo about eXoZymes Inc

Accounting

Judgemental items
Revenue recognition for collaboration services

The business appears to rely on partner and client programs, so timing of performance obligations can affect reported revenue.

Impact: May shift revenue between periods depending on milestones and service delivery

Grant-related funding and support

Government grants and related funding are important to operations and may be recognized differently depending on structure.

Impact: Can create volatility in other income or operating support

Estimates and collectability

A funding-constrained customer base increases the risk of delayed or uncertain collections.

Impact: May affect bad debt expense and working capital

Similar listed companies

Publicly listed companies with a comparable business focus.

Exicure, Inc

XCUR · Pharmaceutical Preparations

Zeo ScientifiX, Inc.

ZEOX · Biological Products, (No Diagnostic Substances)

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

Greenland Mines Ltd

GRMLW · Biological Products, (No Diagnostic Substances)

Zicix Corp

ZICX · Services-Advertising

SL Science Holding Ltd

SLBT · Biological Products, (No Diagnostic Substances)

Last updated: 24/09/2026